Acetazolamide EQL Pharma now approved for sale

The drug Acetazolamide EQL Pharma has now been approved for sale by the Swedish Medicines Agency. The product is expected to be launched around the turn of the year 2018/2019.

Acetazolamide EQL Pharma is used as a short-term treatment for eye surgery when there is a risk of increased pressure inside the eye. Acetazolamide EQL Pharma is also used as an add-on therapy for the treatment of green starr (glaucoma) and before surgery of acute narrow-angle glaucoma.

The drug Acetazolamide EQL Pharma is a niche generic, where EQL Pharma becomes the only and first generic on the Swedish market for more than 60 years. The product is small with about SEK 2.5 million in total annual sales on the Swedish market.

For further information, please contact:

 Christer Fåhraeus
CEO EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com 

About EQL Pharma 

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets 9 niche generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (8) people and is listed on Spotlight Stock Market. EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.